
	MedMira Inc., a biotechnology company, is engaged in the research, development, manufacture, and sale of rapid diagnostics and technology platforms. Its research is focused on specific areas of the diagnostics market, including rapid, point-of-care, and in vitro sectors. Its products include Reveal HIV, which detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal HP/Rapid H. Pylori antibody tests that detect helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection; Reveal TP, a rapid syphilis antibody test, which detects treponema pallidum (TP) antibodies; Multiplo, a line of multiplex tests that combines testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis in whole blood, serum, or plasma; and Miriad developer toolkit that facilitates the development and commercialization of rapid diagnostics. MedMira Inc. sells its rapid tests through a network of medical distributors and strategic business development partners with customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care facilities, governments, and public health agencies. The company sells and distributes its products in North America, Latin America and the Caribbean, Europe, the Asia Pacific, and the Middle East. MedMira Inc. has collaboration with National Research Council of Canada. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. operates as a subsidiary of Onsite Lab Holding AG.
